Harald Reinhart - 23 Jun 2023 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
23 Jun 2023
Net transactions value
+$280,020
Form type
4
Filing time
26 Jun 2023, 16:07:51 UTC
Previous filing
05 Apr 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise $461,725 +18,250 +82% $25.30 40,497 23 Jun 2023 Direct F1, F2
transaction ZLAB American Depositary Shares Tax liability $181,705 -7,182 -18% $25.30 33,315 23 Jun 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -18,250 -25% $0.000000 54,750 23 Jun 2023 American Depositary Shares 18,250 $0.000000 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer.
F3 This transaction represents the disposition of shares to cover taxes.
F4 Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F5 The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases